Swipe Left For English News
中国上海,
2023年2月15日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）被国际知名ESG（环境、社会和公司治理）评级机构Sustainalytics评为2023年“行业最高评级”和“区域（亚太）最高评级”企业。这也是公司连续三年获得该机构的最高评级认可。
Sustainalytics基于企业管理ESG风险的能力对全球企业进行多维度的评估，综合评价企业的风险暴露程度以及其管理能力。今年的评级涵盖了全球42个行业超过1.5万家公司，药明生物被评为“低风险”级别。药明生物的评分在全球近千家制药相关行业企业中位列前2%，并获得亚太地区“区域最高评级”荣誉。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
“我们很自豪同时获评ESG行业和区域最高评级企业，这也证明了药明生物为贯彻ESG战略，为利益相关方创造更大价值作出不懈努力。我们将继续践行ESG战略，引领行业ESG发展，更好地赋能全球合作伙伴发现、开发和生产生物药，造福全球患者。”
药明生物始终秉承可持续发展理念，将ESG战略根植于日常运营，并作为全球业务发展的战略基石。公司出色的ESG表现也获得了MSCI、S&P Global、CDP和EcoVadis等多家全球主要评级机构的高度认可。
推荐阅读
推荐阅读
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过10000名员工。凭借这些员工组成的专业服务团队，以及卓越的技术和洞见，公司为客户提供高效经济的生物药解决方案。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
媒体关系 PR@wuxibiologics.com
业务垂询 info@wuxibiologics.com
WuXi Biologics Recognized as Both Industry and Regional Top-Rated Company by Sustainalytics
SHANGHAI, China,
February 15, 2023
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), is recognized as both 2023 Industry and Regional Top-Rated ESG Company by Sustainalytics. This marks the third consecutive year the company has been awarded by the global provider of Environmental, Social and Governance (ESG) risk ratings.
Sustainalytics assesses companies based on their ability to manage ESG risks. Its multi-dimensional way of measuring ESG risks combines the concepts of management and exposure. This year the ratings cover more than 15,000 companies across 42 industries worldwide, and assess WuXi Biologics as "Low Risk" level. WuXi Biologics ranks top 2% in a total of nearly 1,000 assessed companies of pharmaceutical-related industry, and also receives a ranking of Asia/Pacific "Regional Top-Rated".
Dr. Chris Chen
CEO of WuXi Biologics
Chairman of the company's ESG Committee
We are very proud to be an Industry Top-Rated company and Regional Top-Rated company, which validates our sustainability efforts to ESG strategy and practice. Our ESG performance also shows WuXi Biologics' commitment to creating greater value for our stakeholders. WuXi Biologics will continue to implement ESG strategy and to enable global partners to discover, develop, and manufacture biologics for the benefit of patients worldwide.
WuXi Biologics has set the ESG criteria as an integral part of its business strategy and operations. The company's ESG achievements have been well recognized by multiple major global rating agencies, including MSCI, S&P Global, CDP and EcoVadis.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit:
www.wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
